Sirukumab

DRUG7 trials

Sponsors

Janssen Research & Development, LLC, GlaxoSmithKline, Janssen Pharmaceutica N.V., Belgium

Conditions

Arthritis, RheumatoidAsthmaCritical Confirmed Coronavirus Disease (COVID)-19Giant Cell ArteritisPolymyalgia Rheumatica

Phase 1

A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis

CompletedNCT01636557

Janssen Research & Development, LLCArthritis, Rheumatoid

Start: 2012-10-11End: 2013-10-19Updated: 2017-03-07

Phase 2

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

WithdrawnNCT02794519

GlaxoSmithKlineAsthma

Start: 2016-09-23End: 2016-10-04Updated: 2018-08-31

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

CompletedNCT04380961

Janssen Pharmaceutica N.V., BelgiumCritical Confirmed Coronavirus Disease (COVID)-19

Start: 2020-04-24End: 2021-06-24Updated: 2022-06-21

Phase 3

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

CompletedNCT01604343

Janssen Research & Development, LLCArthritis, Rheumatoid

Start: 2012-08-15End: 2016-12-06Updated: 2018-01-11

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

CompletedNCT01606761

Janssen Research & Development, LLCArthritis, Rheumatoid

Start: 2012-08-06End: 2016-01-12Updated: 2018-03-23

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

TerminatedNCT02531633

GlaxoSmithKlineGiant Cell Arteritis

Start: 2015-10-16End: 2018-03-21Updated: 2019-07-31

Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica

WithdrawnNCT02899026

GlaxoSmithKlinePolymyalgia Rheumatica

Start: 2018-03-15End: 2021-08-26Updated: 2017-11-20

Related Papers

Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumab.

2024-10-03

The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19.

2024-09-022 citations

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.

2022-09-1519 citations

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis.

2020-08-2531 citations

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

2017-08-3048 citations

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

2017-02-1676 citations